IND application submission on track for Q2 2025: MBX 4291, a GLP-1/GIP co-agonist prodrug, is being developed as a once-monthly treatment for obesity. The Company expects to submit an IND application ...

NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, ...

MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is in three ongoing VESPER Phase 2b trials, with data from VESPER-1 expected in mid-2025 MET-233i, a monthly, ultra-long ac ...

Rendering of a planned new addition to North Penn High School, to be built between the school’s current A-pod and F-pod in ...

A bon vivant who overcame a speech impediment and a turbulent youth, Depardieu rose to prominence in the 1970s and became one ...

Local libraries will be bustling with action as they host some of the many free activities in the tri-state area this week.